Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2370
- Registration Number
- NCT00887874
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
PROPACT: Retrospective Prophylaxis Patient Case Collection
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00882778
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1670
- Registration Number
- NCT00877526
- Locations
- 🇲🇾
Novo Nordisk Investigational Site, Selangor Darul Ehsan, Malaysia
A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines
Completed
- Conditions
- Diabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 770
- Registration Number
- NCT00874159
Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 417
- Registration Number
- NCT00873639
- Locations
- 🇷🇴
Novo Nordisk Investigational Site, Bucharest, Romania
Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00873223
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States
Comparison of 2 NovoFine® Needles on the Reflux of Insulin
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Delivery SystemsDiabetes
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00872560
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Chieti, Italy
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
Phase 3
Completed
- Conditions
- Delivery SystemsDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT00871416
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus, Denmark
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66726
- Registration Number
- NCT00869908
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1032
- Registration Number
- NCT00865397
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
© Copyright 2025. All Rights Reserved by MedPath